BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Evolveimmune Therapeutics Inc.

Headquarters: Branford, CT, United States
Year Founded: 2020
Status: Private

BioCentury | Nov 5, 2024
Deals

Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist

Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers 
BioCentury | Dec 14, 2023
Deals

Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal

Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
BioCentury | Nov 10, 2023
Product Development

Costimulatory bispecifics bring new biology to T cell engagers

Abstracts at SICT, ASH describe T cell engagers targeting alternative receptors on the immune cells
BioCentury | Jul 8, 2022
Management Tracks

BI’s Fine becomes president of R&D at EvolveImmune

Plus Sallah joins Genespire as CMO, and updates from Kinaset, Andera, Ariceum and more
Items per page:
1 - 4 of 4